Sort
15,842 grants matching “pancreatic cancer”
Selective inhibition of COPZ1 in PDAC cells
$227,902Roberto Gomes · North Dakota State University · P20 · FY2025 · GM
Project 1: Targeting Metabolic Dependencies in PDAC
$227,876Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2017 · CA
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma
$227,867Buddhadev Layek · North Dakota State University · P20 · FY2025 · GM
Genetic Dissection of Stress Responses in Shwachman-Diamond Syndrome
$227,857Seth Joel Corey · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · DK
T-32 NIH Postdoctoral Training Program in Nanotechnology for Cancer Medicine NTCM
$227,707Denis Wirtz · Johns Hopkins University · T32 · FY2009 · CA
Superoxide, ROS, and novel targets for cancer therapy
$227,666Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
Superoxide, ROS, and novel targets for cancer therapy
$227,666Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Superoxide, ROS, and novel targets for cancer therapy
$227,666Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
Superoxide, ROS, and novel targets for cancer therapy
$227,666Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA
The Role of Carboxypeptidase E in Cancer
$227,596Yoke Peng Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2019 · HD
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
$227,571Daniel Ray Woldring · Michigan State University · R21 · FY2023 · AI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
$227,554Mark R. Kelley · Indiana University Indianapolis · R01 · FY2018 · CA
Alcohol abuse and Endoplasmic Reticulum dysfunction in exocrine pancreas
$227,506Aurelia Lugea · Cedars-Sinai Medical Center · R01 · FY2013 · AA
P-4: Inhibitors of telomerase in treatment of Pancreatic Adenocarcinoma
$227,493Michel M Ouellette · University Of Nebraska Medical Center · P50 · FY2012 · CA
Quantitative Spectroscopic Imaging of Cancer Metabolites in Live Cells and Intact
$227,432Ji-Xin Cheng · Purdue University · R21 · FY2014 · CA
Role of coactivators in cell growth and tumorigenesis
$227,408Hongwu Chen · University Of California At Davis · R01 · FY2009 · CA
Role of coactivators in cell growth and tumorigenesis
$227,408Hongwu Chen · University Of California At Davis · R01 · FY2010 · CA
Role of coactivators in cell growth and tumorigenesis
$227,408Hongwu Chen · University Of California At Davis · R01 · FY2008 · CA
Biospecimen Acquisition, Processing and Classification Unit
$227,351Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · U2C · FY2021 · CA
Advanced Ultrasonic Evaluation of Sentinel Lymph Nodes
$227,153Ernest Joseph Feleppa · Riverside Research Institute · R01 · FY2013 · CA
Determination of solution structures by NMR
$227,139David A Case · Rutgers, The State Univ Of N.J. · R01 · FY2011 · GM
Role of coactivators in cell growth and tumorigenesis
$227,119Hongwu Chen · University Of California At Davis · R01 · FY2007 · CA
Targeting Neuropilin 2 with Semaphorin 3F during Pancreatic Carcinoma Progression
$227,070Diane Renee Bielenberg · Boston Children'S Hospital · R21 · FY2012 · CA
Technology for sensitive and reliable mutational profiling in pancreatic cancer
$227,040G. Mike Makrigiorgos · Dana-Farber Cancer Inst · R21 · FY2009 · CA
KiSS1 treatment of pancreatic adenocarcinoma
$227,040Lacey R McNally · University Of Louisville · R00 · FY2013 · CA